Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Additional Reading from MarketBeat Media
Viking Therapeutics Faces Timeline Risk—But Upside Could Be HugeAuthor: Chris Markoch. Publication Date: 5/1/2026. 
Key Points
- Viking Therapeutics stock reflects the long timelines of clinical-stage biotech, with key VK2735 trial results not expected until 2027.
- The company’s dual-track GLP-1 strategy, including injectable and oral drugs, positions it to compete in a fast-growing weight-loss market.
- Strong cash reserves support operations into 2028, but dilution risk and rising competition remain key concerns for investors.
- Special Report: Have $500? Invest in Elon’s AI Masterplan
Buy the story, sell the news. That’s a reasonable explanation for why Viking Therapeutics (NASDAQ: VKTX) fell more than 3% the day the company delivered its Q1 2026 earnings report. For investors unfamiliar with Viking Therapeutics, it’s important to understand the company is not profitable and remains pre-revenue. That makes evaluating the earnings report by headline numbers misleading. As a clinical-stage biotech, investors should focus on where Viking sits in the FDA timeline to assess risk and reward. The FDA process takes time, and that timeline creates the possibility of sizable long-term returns for investors comfortable with near-term risk. Defining the Opportunity
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itself - it's the infrastructure behind it.
One small-cap company supplies a mission-critical component to Musk's xAI Colossus site that can't be built around. While retail waits for a ticker that doesn't exist yet, early money is moving into this supplier at a fraction of its potential value. See the small-cap stock powering the SpaceX buildout today
Viking is a relatively new player in the GLP-1 space, which is currently dominated by Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO). Both incumbents face the challenge of scaling production to meet surging demand. That’s a good problem for the market, and it leaves room for a company like Viking — which helps explain why investors are "buying the story." Rather than being just another entrant, Viking is pursuing a two-track approach: progressing both an injectable (subcutaneous) and an oral version of its GLP-1 candidate through clinical development. That strategy could help the company differentiate itself if both formulations succeed. Progress Takes TimeThe injectable candidate, VK2735, is further along. Its Phase 2 (VENTURE) trial was completed in 2025 and the results were published in the peer-reviewed journal Obesity in January 2026. Viking reports it has fully enrolled patients in the VANQUISH-1 (adults with obesity) and VANQUISH-2 (adults with obesity and type 2 diabetes) trials. These are 78-week studies, so investors shouldn’t expect topline results until the second half of 2027 at the earliest. The oral formulation of VK2735 is also advancing. Viking completed an end-of-Phase 2 meeting with the FDA in December 2025 and, based on the agency’s feedback, plans to advance the oral candidate into Phase 3. That transition is not expected until Q4 2026, roughly six months behind the injectable program. Timing matters: Viking doesn’t have the field to itself. Companies like Lilly already have oral GLP-1 pills on the market, which could constrain the addressable opportunity even if Viking secures approval. Progress Takes MoneyIf successful, Viking could enter the GLP-1 market with both injectable and oral options — the latter being a clear consumer preference. But moving drugs through late-stage trials requires significant cash. Viking ended the quarter with approximately $603 million in cash and believes that amount is sufficient to fund operations into 2028. That runway should cover the injectable program through clinical development. To help mitigate execution risk, the company has signed a comprehensive agreement with CordenPharma. However, Viking burned more cash than expected during the quarter, which may explain some of the selloff. If cash proves insufficient, the company would likely need to raise capital — probably via a share offering that would dilute existing shareholders. The Wildcard That Could Redefine the OpportunityBeyond VK2735, Viking has filed an investigational new drug (IND) application for VK3019, a novel amylin agonist that targets both the amylin and calcitonin receptors. Those receptors play important roles in regulating food intake and metabolic control. Viking believes dual activation of amylin and calcitonin receptors could offer an attractive option for patients who aren’t candidates for GLP-1 therapies. The company plans to initiate a Phase 1 trial for VK3019 in Q2 2026. How to Make Time Your Friend With VKTXRight now, short interest on VKTX is around 21%, and institutional ownership sits near 76%. That mix can be a headwind for retail investors and helps explain why VKTX is down more than 14% year-to-date in 2026 despite encouraging clinical progress. Still, Viking is followed by 13 analysts who produce a consensus price target of $95.50 — implying a potential upside of more than 200% from current levels. Given the near-term volatility, a measured approach may suit risk-conscious investors. Dollar-cost averaging or establishing a starter position and adding tranches as clinical milestones are achieved can help mitigate downside while allowing participation in the upside if Viking’s programs succeed. |
Post a Comment
Post a Comment